Eric Easom, AN2 Therapeutics CEO
Another RA-backed biotech hits Nasdaq as public market stirs again after a bruising first quarter
California’s AN2 Therapeutics has been on a roll recently.
The lung disease biotech raised $80 million in a Series B back in January, announcing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
